- Home
- BIIB vs ZBH Comparison
BIIB vs ZBH Comparison
Compare BIIB & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ZBH
- Stock Information
- Founded
- BIIB 1978
- ZBH 1927
- Country
- BIIB United States
- ZBH United States
- Employees
- BIIB N/A
- ZBH N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ZBH Industrial Specialties
- Sector
- BIIB Health Care
- ZBH Health Care
- Exchange
- BIIB Nasdaq
- ZBH Nasdaq
- Market Cap
- BIIB 18.7B
- ZBH 19.9B
- IPO Year
- BIIB 1991
- ZBH N/A
- Fundamental
- Price
- BIIB $159.15
- ZBH $88.63
- Analyst Decision
- BIIB Buy
- ZBH Buy
- Analyst Count
- BIIB 24
- ZBH 19
- Target Price
- BIIB $174.62
- ZBH $108.56
- AVG Volume (30 Days)
- BIIB 1.6M
- ZBH 2.2M
- Earning Date
- BIIB 10-30-2025
- ZBH 11-05-2025
- Dividend Yield
- BIIB N/A
- ZBH 1.08%
- EPS Growth
- BIIB N/A
- ZBH N/A
- EPS
- BIIB 10.97
- ZBH 4.03
- Revenue
- BIIB $10,065,900,000.00
- ZBH $8,010,900,000.00
- Revenue This Year
- BIIB $2.97
- ZBH $8.20
- Revenue Next Year
- BIIB N/A
- ZBH $5.92
- P/E Ratio
- BIIB $14.52
- ZBH $21.94
- Revenue Growth
- BIIB 4.77
- ZBH 5.47
- 52 Week Low
- BIIB $110.04
- ZBH $85.33
- 52 Week High
- BIIB $175.86
- ZBH $114.72
- Technical
- Relative Strength Index (RSI)
- BIIB 66.32
- ZBH 31.99
- Support Level
- BIIB $151.83
- ZBH $86.51
- Resistance Level
- BIIB $157.79
- ZBH $90.16
- Average True Range (ATR)
- BIIB 4.88
- ZBH 2.87
- MACD
- BIIB 0.68
- ZBH -1.51
- Stochastic Oscillator
- BIIB 99.65
- ZBH 18.07
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.